Healthcare Policy Lobbyist (Biotech)

EQL Tech•San Francisco, CA

26d•$200,000 - $250,000•Remote

About The Position

The Clinical Trial Abundance Initiative is a new, founder-led effort backed by a coalition of leading science philanthropies, aiming to reform federal policy and law governing clinical trials to make them faster, cheaper, and simpler. The initiative focuses on the 2027 reauthorization of the Prescription Drug User Fee Act (PDUFA) as a key opportunity for reform. This role is a founding leadership position, working closely with the Chief Science Officer to build the effort from the ground up. The work involves shaping legislative and regulatory reform agendas, driving them into the PDUFA 2027 window and its implementation, and building a durable coalition of stakeholders to sustain the work beyond this legislative moment. The focus is on reforming the system that governs clinical trials to increase their abundance, speed, and affordability, rather than on operations, access, diversity, inclusion, or equity.

Requirements

Deep credibility in biotech, life sciences, or FDA / clinical-trial policy — this is a subject-matter role, not a generalist government-affairs one
A track record of being taken seriously by senior, varied stakeholders: Hill offices, agencies, industry executives, investors, and researchers alike
Evidence that you can build something durable, not only win a near-term legislative fight — coalition-building, institution-building, or genuine 0→1 experience
Fluent in the case for reform that expands what's possible — cutting the friction, cost, and time between good science and the patients who need it

Nice To Haves

Direct experience with PDUFA, user-fee reauthorizations, or FDA review-pathway reform
Familiarity with international regulatory models (Australia, UK, EU)
An existing network spanning biotech, investors, research, and DC policy

Responsibilities

Serve as the initiative's lead voice with legislators, congressional staff, and agency officials, and with health-system and industry leaders — building credibility and trust across a wide and varied set of stakeholders
Shape a substantive agenda to reform the policy and law around the cost, speed, and complexity of trials, and drive it into the PDUFA 2027 reauthorization and its implementation
Design and build the coalition — recruiting and aligning companies, investors, research and patient organizations, and allied policymakers into a lasting interest group
Translate the scientific and regulatory case for reform into arguments that move different audiences, in partnership with the Chief Science Officer
Set the initiative's strategy for the years beyond 2027, when the work is field-building rather than chasing a single deadline